AlloVir to Present at the 39th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

AlloVir, Inc. (Nasdaq: ALVR) will present a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021, at 9:10 a.m. ET. An audio-only webcast will be available on the AlloVir website, with an archived replay accessible for 30 days post-event. AlloVir specializes in late clinical-stage cell therapy, focusing on restoring immunity against severe viral diseases in immunocompromised patients using innovative T cell technology. The company is actively advancing multiple mid- and late-stage clinical trials across its product portfolio.

AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, will present a corporate overview at the 39^th Annual J.P. Morgan Healthcare Conference on January 11, 2021 at 9:10 a.m. ET.

An audio-only webcast of the presentation will be available on January 11^th on the Investors & Press section of the AlloVir website at https://ir.allovir.com. An archived replay of the presentation will be available for approximately 30 days following the presentation.

About AlloVir

AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in patients with weakened immune systems. The company’s innovative and proprietary technology platforms leverage off-the-shelf, allogeneic, multi-virus specific T cells targeting devastating viruses for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. AlloVir’s technology and manufacturing process enables the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio. For more information visit www.allovir.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210104005013/en/

FAQ

What presentation will AlloVir give at the J.P. Morgan Healthcare Conference?

AlloVir will present a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021.

When can I access the AlloVir presentation webcast?

The audio-only webcast of AlloVir's presentation will be available on January 11, 2021, on their Investors & Press section of the website.

How long will the AlloVir presentation replay be available?

An archived replay of AlloVir's presentation will be available for approximately 30 days following the event.

What is the focus of AlloVir's research?

AlloVir focuses on restoring natural immunity against life-threatening viral diseases in patients with weakened immune systems.

What technology does AlloVir use in its therapies?

AlloVir employs off-the-shelf, allogeneic multi-virus specific T cells to target devastating viruses in immunocompromised patients.